Drug Approval And Sales GrowthLUPKYNIS has been approved in the U.S. and Europe, with high projections for peak sales and royalties, and a demonstrated strong momentum in its launch with successive positive quarters.
Financial OutlookAurinia is on the path to being cash flow-positive and likely GAAP profitable, with expectations of a 32.5% annual growth in net product revenues and solid guidance for the upcoming year's revenues.
Share Repurchase ProgramAurinia's share repurchase program reflects the Board's confidence in the company's growth prospects and is seen as accretive to shareholders, indicating potential value increase.